Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.46 |
| ▸ | JAK1 | P23458 | 16/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30479381 | 1.00 | JAK2 (0.46) | JAK2JAK1TACR1CCR5 | |
| SCHEMBL3530380 | 0.92 | JAK2 (0.47) | JAK2JAK1TACR1CCR5 | |
| SCHEMBL14272847 | 0.89 | JAK2 (0.45) | JAK2JAK1CCR5 | |
| SCHEMBL20115649 | 0.85 | CCR5 (0.47) | TACR1CCR5 | |
| SCHEMBL16553629 | 0.85 | MEN1 (0.49) | JAK2JAK1TACR1 | |
| SCHEMBL30479357 | 0.84 | CCR5 (0.45) | TACR1CCR5 | |
| SCHEMBL3527380 | 0.84 | CCR5 (0.45) | TACR1CCR5 | |
| SCHEMBL191571 | 0.84 | OPRM1 (0.46) | JAK2JAK1TACR1 | |
| SCHEMBL3528335 | 0.84 | SLC6A3 (0.43) | JAK2JAK1TACR1 | |
| SCHEMBL27640138 | 0.84 | JAK2 (0.41) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088093-B | Acyl sulfonamide nav1.7 inhibitors | 百时美施贵宝公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-3532462-B1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3532462-B1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-13 | — | — | US | disclosed |
| WO-2018081384-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-03 | — | — | WO | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | SCN7A, SCN1A, SCN8A | JAK2 3928/4885JAK1 4552/4885TACR1 1624/4885 |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | SCN7A, SCN1A, SCN8A | JAK2 3928/4885JAK1 4552/4885TACR1 1624/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | JAK2 2862/4885JAK1 2938/4885TACR1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.